drugset / Trial / NCT00495677
A Phase 2 Study Of PF-00232798 In HIV Positive Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PF-00232798 | Small molecule | 5 mg | Oral |
| Comparator | PF-00232798 | Small molecule | 20 mg | Oral |
| Comparator | PF-00232798 | Small molecule | 40 mg | Oral |
| Comparator | PF-00232798 | Small molecule | 150 mg | Oral |
| Comparator | PF-00232798 | Small molecule | 300 mg | Oral |
| Comparator | PF-00232798 | Small molecule | 400 mg | Oral |